Mesotherapy is most widely recognised, particularly in the UK, as an aesthetic technique. Its clinical origins, however, lie elsewhere — and the evidence base supporting its therapeutic use in pain management has grown substantially in recent years.

Introduction

The term was coined in 1958 by the French physician Dr Michel Pistor to describe the intradermal injection of pharmacological agents for the treatment of localised pain, and the technique’s early decades of use were overwhelmingly therapeutic rather than cosmetic. As mesotherapy’s aesthetic applications have grown more prominent over the past three decades, this original pain-management indication has, in many markets, become the less visible half of the discipline.

That balance is shifting back. A 2025 international, multidisciplinary consensus guideline on mesotherapy — drawing on a literature review spanning 1976 to 2023 and structured around 23 clinical questions using PICO methodology — concluded that mesotherapy has accumulated sufficient evidence to support its use across osteoarticular pain, rehabilitation, and dermo-aesthetic indications, describing the field as moving decisively from a practice
“based on personal beliefs”
toward one grounded in evidence-based recommendations.

Mechanism of Action

Mesotherapy for pain is more accurately described, in much of the recent literature, as
local intradermal therapy (LIT)
— a term proposed to emphasise that the clinical effect is achieved through superficial, dermal-layer inoculation rather than deeper or systemic drug delivery.

In practice, most clinical mesotherapy for pain likely benefits from a combination of these mechanisms rather than any single one in isolation, and the Society encourages members to communicate this nuance accurately rather than overstating any one proposed pathway as definitively established.

The Evidence Base: Chronic Pain

Chronic back pain
has the most substantial body of evidence within musculoskeletal mesotherapy. A 2025 narrative review analysing nine studies and more than 800 patients with chronic back pain syndrome found a consistent positive impact on both pain reduction and functional improvement, with no serious adverse events reported. The review describes an emerging
three-step approach
: risk factor assessment, medical intervention via mesotherapy, and subsequent, targeted physiotherapy.

Musculoskeletal disorders more broadly
were the subject of a systematic review with meta-analysis restricted to high-quality randomised controlled trials. Across seven studies meeting inclusion criteria, a statistically significant reduction in Visual Analogue Scale pain scores was observed in the mesotherapy group compared with control in all but one trial. The authors note a meaningful secondary benefit: earlier pain relief may allow earlier patient access to physiotherapy and occupational therapy.

Knee osteoarthritis
has been examined in a randomised controlled trial of 43 patients (56 knees) with mild-to-moderate disease, comparing mesotherapy against saline control — contributing to a still-developing but clinically meaningful evidence base, of particular relevance given the population-level burden of knee osteoarthritis.

Cervicobrachial and neck pain
has been studied using diclofenac sodium and lidocaine injected into the trapezius over a six-week protocol, assessed via Visual Analogue Scale, range of motion, and objective muscle tone measurement using myotonometry — a model for the more rigorous, objectively-measured protocol design the Society encourages members to adopt where feasible.

The Evidence Base: Acute and Post-Acute Pain

Mesotherapy’s evidence base in genuinely acute pain is less extensive than in chronic musculoskeletal indications, but a relevant body of work has emerged around
post-acute and subacute pain syndromes
, most notably post-COVID pain syndrome. A retrospective cohort study of 96 patients with both nociceptive and neuropathic pain components found mesotherapy to be an easily applicable, cost-effective, and well-tolerated intervention, with a favourable side-effect profile relative to systemic alternatives.

Members should note that
acute nonspecific neck pain
has also been studied using single intracutaneous injections of local anaesthetic and steroid in a randomised controlled design, supporting feasibility in genuinely acute presentations, though this remains a comparatively narrow slice of the acute pain literature.

Safety Profile

A consistent theme across the reviewed literature is a favourable safety profile, with the chronic back pain review noting no serious adverse events across more than 800 patients. The technique’s drug-sparing rationale is itself a relevant safety consideration, particularly where the alternative would involve repeated systemic NSAID or steroid dosing.

Limitations of the Current Evidence

The Society considers it important to state these plainly.
Standardisation remains incomplete
: protocols vary considerably in injection site, drug combination, dosing, and session frequency.
Trial quality is uneven
, with many studies retrospective, small, or lacking a control group.
Mechanism remains incompletely established
, with no single pathway definitively isolated as dominant.

Clinical and Practice Implications for Members

Chronic back pain and musculoskeletal pain currently represent the indications with the strongest supporting evidence, and framing mesotherapy within a structured, multidisciplinary pathway is consistent with current best-practice thinking. Where multiple agents are considered for a single injectate, the current absence of robust intradermal drug-interaction data warrants caution. Patients should be counselled honestly about the maturity of the evidence base, and members should avoid presenting mesotherapy as a definitively superior alternative to established first-line care where such claims are not yet supported.

Conclusion

Mesotherapy’s origins in pain management predate its now more widely recognised aesthetic applications, and the evidence accumulated since supports a genuine, if still maturing, clinical role for the technique in modern pain practice. The Society’s position is that this evidence should be communicated with the same standard of accuracy and proportion expected across all applications of mesotherapy: real benefit, honestly described, without overstatement.

References

1. International Consensus Guidelines on the Safe and Evidence-Based Practice of Mesotherapy: A Multidisciplinary Statement.
   J Clin Med.
   2025;14(13):4689.
2. The role of mesotherapy in chronic back pain syndrome: what do we know?
   Rheumatol Int.
   2025;45(9):206.
3. Safety and efficacy of mesotherapy in musculoskeletal disorders: a systematic review of randomized controlled trials with meta-analysis.
   PMC.
4. Efficacy of mesotherapy for pain, function and quality of life in patients with mild and moderate knee osteoarthritis: a randomized controlled trial.
   PMC.
5. Effectiveness of mesotherapy in post-COVID pain syndrome: retrospective cohort study of 96 patients.
   ScienceDirect.
   2024.
6. Effects of intradermal therapy (mesotherapy) on bilateral cervicobrachial pain.
   J Pers Med (MDPI).
   2024;14(1):122.
7. Intradermal therapy (mesotherapy): the lower the better.
   PubMed.
   2022.
8. Mammucari M, et al. Mesotherapy: from historical notes to scientific evidence and future prospects.
   Sci World J.
   2020.
9. Mammucari M, et al. Role of mesotherapy in musculoskeletal pain: opinions from the Italian Society of Mesotherapy.
   Evid Based Complement Alternat Med.
   2012.